Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SomaLogic Inc. Warrant (SLGCW)
| -28.3 | -44.2 | -52.2 | -80.5 | -- | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2023
|
|---|---|
|
SomaLogic Inc. Warrant (SLGCW)
| -70.0 |
|
BSE Sensex
| 18.7 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout SomaLogic Inc. Warrant (SLGCW)
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific... for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado. Read more
-
Exec. Chairman
Mr. Troy M. Cox M.B.A.
-
Exec. Chairman
Mr. Troy M. Cox M.B.A.
-
Headquarters
Boulder, CO
-
Website
FAQs for SomaLogic Inc. Warrant (SLGCW)
What is the current share price of SomaLogic Inc Warrant (SLGCW) Today?
The share price of SomaLogic Inc Warrant (SLGCW) is $0.09 (NASDAQ) as of 05-Jan-2024 15:52 EDT. SomaLogic Inc Warrant (SLGCW) has given a return of -80.45% in the last 1 years.
What is the current PB & PE ratio of SomaLogic Inc Warrant (SLGCW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.68 |
0.13 |
2021 |
-7.02 |
0.99 |
2020 |
-- |
-- |
2022 |
-0.68 |
0.13 |
2021 |
-7.02 |
0.99 |
What is the 52 Week High and Low of SomaLogic Inc Warrant (SLGCW)?
The 52-week high and low of SomaLogic Inc Warrant (SLGCW) are Rs -- and Rs -- as of 28-Aug-2026.
What is the market cap of SomaLogic Inc Warrant (SLGCW)?
SomaLogic Inc Warrant (SLGCW) has a market capitalisation of -- as on 25-Jan-2024. As per SEBI classification, it is a company.
Should I invest in SomaLogic Inc Warrant (SLGCW)?
Before investing in SomaLogic Inc Warrant (SLGCW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.